Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.
Ii protein suppression is a promising antisense drug-based therapy that dramatically enhances the immunogenicity of tumor cell major histocompatibility complex class II-presented antigenic epitopes. The strength of this approach is that the antisense only needs to be transiently effective in a fraction of the tumor cells. The systemic antitumor immune response generated subsequently eradicates both directly treated cells and distant tumor deposits. The drugs and mechanisms of this therapy are considered, in addition to practical developmental questions.
Xu
Minzhen
M
Antigen Express Inc., 100 Barber Avenue, Worcester, MA 01606, USA.
Lu
Xueqing
X
Kallinteris
Nikoletta L
NL
Wang
Yu
Y
Wu
Shuzhen
S
von Hofe
Eric
E
Gulfo
Joseph V
JV
Humphreys
Robert E
RE
Hillman
Gilda G
GG
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D000944:Antigens, Differentiation, B-Lymphocyte / Q000235:genetics / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D002986:Clinical Trials as Topic; D005802:Genes, MHC Class II; D015316:Genetic Therapy / Q000379:methods*; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009369:Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*
D000944:Antigens, Differentiation, B-Lymphocyte; D000951:Antigens, Neoplasm; D000949:Histocompatibility Antigens Class II; D016376:Oligonucleotides, Antisense; C045084:invariant chain